[go: up one dir, main page]

WO2009033078A3 - Compositions and methods for controlling cholesterol levels - Google Patents

Compositions and methods for controlling cholesterol levels Download PDF

Info

Publication number
WO2009033078A3
WO2009033078A3 PCT/US2008/075471 US2008075471W WO2009033078A3 WO 2009033078 A3 WO2009033078 A3 WO 2009033078A3 US 2008075471 W US2008075471 W US 2008075471W WO 2009033078 A3 WO2009033078 A3 WO 2009033078A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
hdl
methods
patient
cholesterol levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/075471
Other languages
French (fr)
Other versions
WO2009033078A2 (en
Inventor
Raif Tawakol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/899,284 external-priority patent/US20080058292A1/en
Application filed by Individual filed Critical Individual
Publication of WO2009033078A2 publication Critical patent/WO2009033078A2/en
Publication of WO2009033078A3 publication Critical patent/WO2009033078A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a method for reducing flushing in a patient and for for increasing HDL and/or HDL-2b levels in a patient, with compositions being administered to the patient only twice a day, from 30 to 60 minutes after lunch and 30 to 60 minutes after dinner. In some embodiments, the compositions include an adipocyte G-protein antagonist, a PPAR-α agonist, and a PPAR-γ agonist in amounts effective in to provide a synergistic therapeutic HDL increasing effect, and/or a synergistic therapeutic HDL-2b increasing effect.
PCT/US2008/075471 2007-09-05 2008-09-05 Compositions and methods for controlling cholesterol levels Ceased WO2009033078A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/899,284 2007-09-05
US11/899,284 US20080058292A1 (en) 2003-10-29 2007-09-05 Method for increasing HDL and HDL-2b levels
US96779707P 2007-09-07 2007-09-07
US60/967,797 2007-09-07

Publications (2)

Publication Number Publication Date
WO2009033078A2 WO2009033078A2 (en) 2009-03-12
WO2009033078A3 true WO2009033078A3 (en) 2009-08-20

Family

ID=40429379

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/075471 Ceased WO2009033078A2 (en) 2007-09-05 2008-09-05 Compositions and methods for controlling cholesterol levels
PCT/US2008/075465 Ceased WO2009033072A1 (en) 2007-09-05 2008-09-05 Compositions and methods for controlling cholesterol levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075465 Ceased WO2009033072A1 (en) 2007-09-05 2008-09-05 Compositions and methods for controlling cholesterol levels

Country Status (1)

Country Link
WO (2) WO2009033078A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
EP3622948A1 (en) 2018-09-11 2020-03-18 I.P.S. International Products & Services S.r.l. Multilayered formulations with dual release rate of one or more active principles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20040097593A1 (en) * 1999-11-08 2004-05-20 Partha Neogi Compounds for treatment of inflammation, diabetes and related disorders
US20050148556A1 (en) * 2003-10-29 2005-07-07 Raif Tawakol Compositions and methods for increasing HDL and HDL-2b levels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087048A1 (en) * 2001-05-31 2007-04-19 Abrams Andrew L Oral dosage combination pharmaceutical packaging
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20040097593A1 (en) * 1999-11-08 2004-05-20 Partha Neogi Compounds for treatment of inflammation, diabetes and related disorders
US20050148556A1 (en) * 2003-10-29 2005-07-07 Raif Tawakol Compositions and methods for increasing HDL and HDL-2b levels

Also Published As

Publication number Publication date
WO2009033072A1 (en) 2009-03-12
WO2009033078A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
EP1977746B8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2010132882A8 (en) Sublingual dexmedetomidine compositions and methods of use thereof
GB0718905D0 (en) Methods, compositions and formulations for the treatment of thyroid eye disease
WO2006130522A3 (en) Methods and compositions for managing psychotic disorders
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
WO2007081710A3 (en) Treatment modalities for autoimmune diseases
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL198460A (en) Use of 3-alpha-androstanediol and a 5-ht1a agonist in the preparation of a medicament for the on demand treatment of sexual dysfunction
IL198723A0 (en) Methods and compositions for therapeutic treatment
WO2007058990A3 (en) Therapy using cytokine inhibitors
ZA200807802B (en) Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels
WO2008057196A3 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
WO2009033078A3 (en) Compositions and methods for controlling cholesterol levels
WO2010041140A3 (en) Treatment of proliferative disorders with a death receptor agonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829108

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24.06.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08829108

Country of ref document: EP

Kind code of ref document: A2